secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001599298-23-000092
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab shows 18-fold increased PD-1 binding affinity in presence of VEGF at SITC
--------------------------------------------------------------------------------

- Poster at SITC 2023 details cooperative binding: 18x higher PD-1 affinity with VEGF present in vitro.
- Tetravalent bispecific antibody designed for higher avidity in tumor microenvironment vs. healthy tissue.
- Ongoing Phase III trials HARMONi (EGFR-mutated NSCLC) and HARMONi-3 (squamous NSCLC).
- Over 950 patients treated with ivonescimab across studies in China, Australia, and Summit territories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000092/0001599298-23-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000092/smmt-20231031.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer